Cargando…

Comparison of bortezomibcyclophosphamide- dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients

The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the last decades, with an improved median survival of 8-10 years. This study aimed to evaluate the bortezomib, cyclophosphamide and dexamethasone (VCD) regimen versus bortezomib and dexamethasone (VD) regi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciftciler, Rafiye, Goker, Hakan, Buyukasik, Yahya, Sayınalp, Nilgun, Haznedaroglu, Ibrahim C., Aksu, Salih, Ozcebe, Osman, Demiroglu, Haluk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212206/ https://www.ncbi.nlm.nih.gov/pubmed/32399162 http://dx.doi.org/10.4081/hr.2020.8267

Ejemplares similares

Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation
por: Çiftçiler, Rafiye, et al.
Publicado: (2021)

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019)

The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

The Factors Affecting Early Death in Newly Diagnosed APL Patients
por: Ciftciler, Rafiye, et al.
Publicado: (2019)

Indications and Outcomes of Splenectomy for Hematological Disorders
por: Ciftciler, Rafiye, et al.
Publicado: (2019)

CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation
por: ALADAĞ, Elifcan, et al.
Publicado: (2020)

Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency
por: ALADAĞ, Elifcan, et al.
Publicado: (2019)

Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma
por: Demiroğlu, Haluk, et al.
Publicado: (2021)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013)

Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia
por: Serefhanoglu, Songul, et al.
Publicado: (2010)

Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma
por: Ghasemi, Mehdi, et al.
Publicado: (2016)

Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature
por: UZ, Burak, et al.
Publicado: (2013)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
por: Eliaçık, Eylem, et al.
Publicado: (2015)

Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems
por: Bektaş, Özlen, et al.
Publicado: (2016)

Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission
por: Aydın, Mürüvvet Seda, et al.
Publicado: (2017)

The effects of blood group types on the risk of COVID-19 infection and its clinical outcome
por: GÖKER, Hakan, et al.
Publicado: (2020)

Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation
por: KARATAŞ, Ayşe, et al.
Publicado: (2022)

The Prognosis of Adult Burkitt’s Cell Leukemia in Real-Life Clinical Practice
por: Malkan, Ümit Yavuz, et al.
Publicado: (2016)

A single-center experience of haploidentical stem cell transplantation in hematological malignancies
por: MALKAN, Ümit Yavuz, et al.
Publicado: (2022)

The clinical course of COVID-19 in hematopoietic stem cell transplantation (HSCT) recipients
por: KARATAŞ, Ayşe, et al.
Publicado: (2021)

Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells
por: Uz, Burak, et al.
Publicado: (2014)

Prophylactic Central Nervous System Irradiation Is Not Indispensable in Adult Patients with Acute Lymphoblastic Leukemia: A Multicenter Retrospective Cohort Study
por: Çınar, Olgu Erkin, et al.
Publicado: (2022)

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study
por: ÇİFTÇİLER, Rafiye, et al.
Publicado: (2019)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study
por: Aladağ, Elifcan, et al.
Publicado: (2021)

Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
por: Sauer, Sandra, et al.
Publicado: (2023)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma
por: Karataş, Ayşe, et al.
Publicado: (2020)

Alternating bortezomib-dexamethasone and lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma aged over 75 years
por: Yokoyama, Akihiro, et al.
Publicado: (2022)

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
por: Huo, Zhongjun, et al.
Publicado: (2022)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
por: Rosiñol, Laura, et al.
Publicado: (2023)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
por: Jacobus, S J, et al.
Publicado: (2016)

On Being a “Physician Patient” with His Own Experimental Therapeutic Drug
por: Çiftçiler, Rafiye, et al.
Publicado: (2018)

COVID-19, Renin-Angiotensin System, and Hematopoiesis
por: Çiftçiler, Rafiye, et al.
Publicado: (2020)

Pathobiological Interactions of Local Bone Marrow Renin-Angiotensin System and Central Nervous System in Systemic Arterial Hypertension
por: Ciftciler, Rafiye, et al.
Publicado: (2020)

Ankaferd hemostat: from molecules to medicine
por: ÇİFTÇİLER, Rafiye, et al.
Publicado: (2020)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sldg8v9f7q64l2e269ja8s59o6